MAYBAKER Stock Overview
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
May & Baker Nigeria plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₦8.00 |
| 52 Week High | ₦8.50 |
| 52 Week Low | ₦4.75 |
| Beta | -0.042 |
| 11 Month Change | 17.65% |
| 3 Month Change | 14.29% |
| 1 Year Change | 60.00% |
| 33 Year Change | 78.17% |
| 5 Year Change | 290.24% |
| Change since IPO | 497.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAYBAKER | NG Pharmaceuticals | NG Market | |
|---|---|---|---|
| 7D | 2.6% | -1.0% | 0.9% |
| 1Y | 60.0% | 0.8% | 54.4% |
Return vs Industry: MAYBAKER exceeded the NG Pharmaceuticals industry which returned 0.8% over the past year.
Return vs Market: MAYBAKER exceeded the NG Market which returned 54.4% over the past year.
Price Volatility
| MAYBAKER volatility | |
|---|---|
| MAYBAKER Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in NG Market | 9.2% |
| 10% least volatile stocks in NG Market | 3.2% |
Stable Share Price: MAYBAKER has not had significant price volatility in the past 3 months compared to the NG market.
Volatility Over Time: MAYBAKER's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 388 | Patrick Ajah | may-baker.com |
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic, anti-hypersensitive, anti-infective, anti-malaria, analgesic, cough and cold, and anxiolytics; and nature care products.
May & Baker Nigeria plc Fundamentals Summary
| MAYBAKER fundamental statistics | |
|---|---|
| Market cap | ₦13.80b |
| Earnings (TTM) | ₦2.26b |
| Revenue (TTM) | ₦27.22b |
6.1x
P/E Ratio0.5x
P/S RatioIs MAYBAKER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAYBAKER income statement (TTM) | |
|---|---|
| Revenue | ₦27.22b |
| Cost of Revenue | ₦18.74b |
| Gross Profit | ₦8.47b |
| Other Expenses | ₦6.21b |
| Earnings | ₦2.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 31.14% |
| Net Profit Margin | 8.30% |
| Debt/Equity Ratio | 49.8% |
How did MAYBAKER perform over the long term?
See historical performance and comparison